Clinical Trials Browser

Phase 1/2 × OTHER × aflutinib × Clear all

NCT07087223 2025-07-25

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Phase 1/2 Recruiting

Non Small Cell Lung Cancer NSCLC

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Phase 1/2 Unknown

Adenocarcinoma of Lung, Neoplasm, Residual